Article

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

2023-12-11

Abstract excerpt

<h4>Summary</h4> Clinical effectiveness of KRAS G12C inhibitors (G12Cis) is limited both by intrinsic and acquired resistance, necessitating the development of combination approaches. We found that targeting proximal receptor tyrosine kinase (RTK) signaling using the SOS1 inhibitor (SOS1i) BI-3406 both enhanced the potency of and delayed resistance to G12Ci treatment, but the extent of SOS1i effectiveness was mod...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7e496ca3-ca36-59f7-b4a8-3e9ca6316f4a
DOI: 10.1101/2023.12.07.570642

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinomaDOI 10.1101/2023.12.07.570642Read

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity Read

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.Semantic proximity Read

Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.Semantic proximity Read

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.Semantic proximity Read

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read